Subclinical Hypothyroidism in PCOS: Impact on Presentation, Insulin Resistance, and Cardiovascular Risk
Table 3
Clinical and biochemical characteristics of SCH PCOS, euthyroid PCOS, and euthyroid control subjects.
SCH PCOS () (mean ± SD)
Euthyroid PCOS () (mean ± SD)
Euthyroid control () (mean ± SD)
value
Age (years)
29.21 ± 5.9
26.37 ± 4.5
28.1 ± 3.9
NS
BMI (Kg/m2)
32.70 ± 4.9
30.91 ± 5.1
27.3 ± 4.7
0.01
Hypertension (%)
7 (25.9)
11 (16.17)
5 (5.5)
0.008
Hirsutism (%)
25 (92%)
51 (75%)
4 (5%)
0
Ferriman and Gallwey score
20.91 ± 5.3
18.37 ± 4.9
8.21 ± 4.3
0.1
LH
13.12 ± 7.6
11.39 ± 6.8
5.81 ± 3.7
0.02
FSH
4.7 ± 1.9
4.8 ± 1.8
4.41 ± 1.9
NS
LH/FSH ratio
2.9 ± 0.5
2.7 ± 0.7
1.01 ± 0.29
NS
Free T3 (pg/mL)
2.42 ± 1.3
2.82 ± 1.3
3.73 ± 0.7
NS
Free T4 (ng/dL)
1.02 ± 1.0
1.23 ± 1.1
1.32 ± 1.6
NS
TSH (mIU/mL)
7.2 ± 3.5
3.1 ± 1.5
3.2 ± 1.2
<0.01
Anti-TPO ab (IU/mL)
139.54 ± 51.7
32.59 ± 5.1
19.34 ± 10.3
<0.001
Free testosterone (pg/mL)
23.09 ± 6.3
18.34 ± 7.9
12.2 ± 5.7
<0.01
Estradiol (pg/mL)
59.31 ± 18.6
63.83 ± 26.7
74.24 ± 29.26
NS
Progesterone (ng/mL)
2.5 ± 0.6
2.9 ± 1.2
7.4 ± 4.3
NS
HOMA-IR
4.2 ± 1.1
2.8 ± 1.4
1.8 ± 0.7
0.01
Total cholesterol (mg/dL)
230 ± 29.6
198 ± 23.1
159 ± 24.8
0.01
Triglycerides (mg/dL)
136 ± 21.3
120 ± 16.7
84.3 ± 10.6
0.001
LDL Chol. (mg/dL)
151 ± 17.3
139 ± 12.6
109 ± 20.4
0.02
HDL Chol. (mg/dL)
37.4 ± 15.4
45.9 ± 9.6
60.3 ± 5.2
0.04
= NS between SCH PCOS and euthyroid PCOS, between SCH PCOS and euthyroid controls, and between euthyroid PCOS and euthyroid control group on post hoc analysis. = NS between SCH PCOS and euthyroid PCOS group, = NS between SCH PCOS and euthyroid controls, and = NS between euthyroid PCOS and euthyroid control group on post hoc analysis. between SCH PCOS and euthyroid PCOS group, between SCH PCOS and euthyroid controls, and = NS between euthyroid PCOS and euthyroid control group on post hoc analysis. between SCH PCOS and euthyroid PCOS group, between SCH PCOS and euthyroid controls, and between euthyroid PCOS and euthyroid control group on post hoc analysis.
